Improving Pancreatic Cancer Care by the Use of Computational Science and Technology (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT06055010

Recruitment Status : Recruiting

First Posted : September 26, 2023

Last Update Posted : September 26, 2023

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Catharina Ziekenhuis Eindhoven

St. Antonius Hospital

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

University Medical Center Groningen

Medisch Spectrum Twente

Erasmus Medical Center

Maastricht University Medical Center

Leiden University Medical Center

NYU Langone Health

Johns Hopkins University

Delft University of Technology

Information provided by (Responsible Party):

Lois Daamen, UMC Utrecht

Study Description

Brief Summary:

The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.

Condition or disease	Intervention/treatment
Pancreatic Cancer Pancreatic Cyst Pancreatic Adenocarcinoma Pancreatic Diseases Pancreas Adenocarcinoma Pancreas Cyst	Other: No interventions

Show detailed description

Detailed Description:

Study design: Retrospective, multicenter observational cohort study. Pseudonymized data will be collected retrospectively. Clinical data from patients who underwent diagnostic procedures and treatment for (suspected) benign and malignant pancreatic lesions can be retrieved from the institutional and audit databases and ongoing cohorts of the participating centers. For the collection of clinical data, a Castor Electronic Data Capture (EDC) database will be used. Imaging data, including pseudonymized radiographic images prior to, during and after treatment will be collected via Research Imaging Architecture (RIA) folders and securely stored within the University Medical Center (UMC) Utrecht. Data for artificial intelligence projects can be requested from the central database and is securely shared after approval of each participating site. For this purpose, a project steering committee will be established, which shall consist of one representative of each participating center. The steering committee will be responsible for the overall management of the project, addressing and resolving project management problems, assessing study proposals and deciding on the disclosure of a dataset to the requesting party as described in the Research Collaboration Agreement. Collected data within the consortium database (e.g. preoperative scans, postoperative scans, disease entities, annotations et cetera) will be listed to provide a clear overview of available data.

Study population: All patients who underwent diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP), as well as healthy individuals who received an abdominal CT-scan (controls).

Primary objective: The primary endpoint of this study is dependent on the specific subprojects. This study will facilitate the collection of large amounts of real-world data for (future) computer science projects. The focus of currently prespecified subprojects for the different participating centers are presented below:

PI Lois Daamen (Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center): To develop an explainable AI (XAI) algorithm that can support clinicians with early local recurrence detection after surgery and local tumor response assessment during (neo)adjuvant and/or definitive chemotherapy and/or radiotherapy in individual patients with pancreatic cancer using common diagnostic modalities. Use of deep learning body composition analysis of clinically acquired Computed Tomography (CT)-scans for personalized chemotherapy dose modification based on (predicted) toxicity profiles.
PI Misha Luyer (Catharina Ziekenhuis Eindhoven): Improved diagnosis and characterization of pancreatic tumors and its relation with surrounding structures. Early detection of primary pancreatic cancer, resectability of pancreatic tumors and evaluation of response to neoadjuvant chemo(radio)therapy.
PI's Jeanin van Hooft, Sven Mieog (Leiden University Medical Center): (Semi)automated pancreas segmentation on Magnetic Resonance Imaging (MRI), development of a classification algorithm for the detection of primary pancreatic cancer and high-grade premalignant lesions on MRI, quantification of longitudinal changes of pancreatic tissue on MRI that may indicate the development of pancreatic cancer. To integrate 3D models of radiological modalities (CT, MRI and PET) to better predict resectability and treatment response of pancreatic tumors.
PI Steven Olde Damink (Maastricht University Medical Center): To define a host phenotype based on medical imaging (body composition variables and radionomics based on CT-imaging analyses) for pancreatic cancer patients to predict postoperative and oncological outcomes.
PI's Joost Klaasse (University Medical Center Groningen) & Mike Liem (Medisch Spectrum Twente): Use of artificial intelligence for pancreatic cysts.
PI Inez Verpalen (Amsterdam University Medical Center): To develop (1) a model for pancreatic cancer neoadjuvant response evaluation using CT scans (survival and pathology (PA) as outcome), (2) a model for pancreatic carcinoma resectability assessment using CT scans, (3) a multicenter pancreatic carcinoma + vessel segmentation model, (4) a postoperative pancreatic fistula (POPF) prediction model using MRI; (5) an Intraductal papillary mucinous neoplasms (IPMN) segmentation model in MRI; (6) a model for malignancy estimation for IPMN and to perform (7) external validation of POPF prediction using radiomics on CT.
PI Bas Groot Koerkamp (Erasmus Medical Center): i.a. PREOPANC-related projects

Data collection: The following clinical data will be collected:

Age (years)
Gender
Height (cm)
Weight (kg)
Calculated body mass index (BMI; kg/m2)
Comorbidity/American Society of Anesthesiologists (ASA) score
Eastern Cooperative Oncology Group (ECOG) performance score
Date of treatment
Type of treatment (i.e. chemotherapy, radiotherapy, surgery, combinations)
Complications
Histopathological diagnosis
Vascular resection
Resection margin status (R0/R1/R2)
Tumor differentiation
Tumor size
Pathological tumor, node, metastasis (pTNM) stage
Number of positive lymph nodes
Presence of recurrence
Date of recurrence
Recurrence site
Vital status
Date of death
Date of last follow-up Data will be drawn as much as possible from existing clinical databases, including the "Pancreatic Cancer Recurrence in the Netherlands" database (NCT04605237), which includes most of these variables.

Technical data:

Pre- and post-treatment (follow-up) CT scans
Pre- and post-treatment (follow-up) MRI scans
Pre- and post-treatment (follow-up) PET-CT scans

Data management is carried out in accordance with the UMC Utrecht Data management policy, as described in the Data Management Plan. Data is collected using a predefined, electronic case record form in Castor EDC. Local clinicians in the participating centers are responsible for data collection. They can, however, transfer this responsibility to the study team. The study team will appoint appropriate personnel for data collection.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	5000 participants
Observational Model:	Cohort
Time Perspective:	Retrospective
Official Title:	Improving Pancreatic Cancer Care by the Use of Computational Science and Technology
Actual Study Start Date :	January 1, 2014
Estimated Primary Completion Date :	December 31, 2029
Estimated Study Completion Date :	December 31, 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatic Cancer

Genetic and Rare Diseases Information Center resources: Pancreatic Cancer

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
Healthy individuals Healthy individuals who received an abdominal CT-scan (controls).	Other: No interventions Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
Individuals with pancreatic lesions Patients who received diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database	Other: No interventions Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.

Outcome Measures

Primary Outcome Measures :

Subproject dependent [ Time Frame: Through study completion, an average of 5 years. ]
Endpoints within this project are dependent on the specific subprojects. This study will facilitate the collection of large amounts of real-world data for (future) computer science projects.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

All patients who underwent diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database, as well as healthy individuals who received an abdominal CT-scan (controls).

Criteria

Inclusion Criteria:

≥18 years of age
Patients who received diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)

Exclusion Criteria:

- Subjects who object to the use of their data for the purpose of scientific research

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06055010

Contacts

Layout table for location contacts

Contact: Lois A Daamen, MD, PhD	+31651223276	l.a.daamen-3@umcutrecht.nl

Locations

Layout table for location information

Netherlands
Regional Academic Cancer Center Utrecht	Recruiting
Utrecht, Netherlands, 3584 CX
Contact: Lois A Daamen, MD, PhD 0651223276 l.a.daamen-3@umcutrecht.nl

Sponsors and Collaborators

UMC Utrecht